Live Analyst Rating Changes 24522 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/William Pickering
BERN

William Pickering

Bernstein
Wall Street Analyst
★★★☆☆
#1156
on 13Foresight · ranked by our own returns
61%
Success Rate
+10.4%
Average Return
11 of 18 calls profitable · +0.4% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 61% of William Pickering's ratings turned a profit when each position was held for 1 year — averaging +10.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

49 Buy 40 Hold 0 Sell
William's Stock Coverage 17 ratings · 2026-08-14
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
VRTX
Vertex Pharmaceuticals
 Aug 11, 2026 BUY Strong Buy
-14.1% avg upside
62 analysts
$608.00
17.78% Upside
 -0.7% ·
ARWR
Arrowhead Pharmaceuticals
 May 13, 2026 HOLD Strong Buy
-12.5% avg upside
27 analysts
$46.00
46.22% Downside
 +12.0% ·
DYN
Dyne Therapeutics
 May 13, 2026 HOLD Strong Buy
+53.5% avg upside
31 analysts
$24.00
7.65% Downside
 +39.4% ·
BEAM
Beam Therapeutics
 May 13, 2026 BUY Strong Buy
+96.3% avg upside
25 analysts
$39.00
47.15% Upside
 -16.9% ·
CRSP
Crispr Therapeutics AG
 May 13, 2026 HOLD Buy
+40.1% avg upside
41 analysts
$56.00
3.68% Upside
 +0.8% ·
NTLA
Intellia Therapeutics
 May 13, 2026 HOLD Buy
+226.5% avg upside
37 analysts
$17.00
43.69% Upside
 -17.0% ·
BBIO
BridgeBio Pharma
 May 08, 2026 BUY Strong Buy
+16.6% avg upside
34 analysts
$114.00
40.43% Upside
 +18.9% ·
BMRN
BioMarin Pharmaceutical
 May 05, 2026 BUY Strong Buy
+38.4% avg upside
52 analysts
$82.00
19.71% Upside
 +27.0% ·
ALNY
Alnylam Pharma
 May 01, 2026 BUY Strong Buy
+42.7% avg upside
51 analysts
$447.00
96.88% Upside
 -23.0% ·
ALLO
Allogene Therapeutics
 Apr 14, 2026 HOLD Strong Buy
+667.0% avg upside
28 analysts
$3.85
94.35% Upside
 -11.0% ·
REGN
Regeneron
 Apr 08, 2026 BUY Strong Buy
-2.8% avg upside
58 analysts
$921.00
14.37% Upside
 +3.0% ·
SRPT
Sarepta Therapeutics
 Mar 25, 2026 HOLD Buy
+223.8% avg upside
49 analysts
$20.00
8.67% Upside
 -29.4% ·
ROIV
Roivant Sciences
 Mar 20, 2026 BUY Strong Buy
-2.0% avg upside
17 analysts
$35.00
3.53% Downside
 +30.8% ·
IMVT
Immunovant
 Mar 20, 2026 HOLD Strong Buy
-4.2% avg upside
24 analysts
$28.00
33.09% Downside
 +81.1% ·
BIIB
Biogen
 Feb 06, 2026 HOLD Strong Buy
+20.6% avg upside
52 analysts
$201.00
4.64% Downside
 +3.8% ·
IONS
Ionis Pharmaceuticals
 Jan 13, 2026 HOLD Strong Buy
+41.7% avg upside
43 analysts
$89.00
59.35% Upside
 -28.4% ·
BHVN
Biohaven Ltd.
 Nov 06, 2025 HOLD Strong Buy
+55.3% avg upside
25 analysts
$9.00
39.38% Downside
 +71.9% ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
William Pickering — Frequently Asked Questions
How accurate are William Pickering's stock ratings?
Based on the calls 13Foresight could measure, about 61% of William's ratings were profitable over a one-year hold, with an average return of +10.2% per rating, or +0.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is William ranked on 13Foresight?
William Pickering is currently ranked #1156 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does William cover?
William most recently has ratings on VRTX, ARWR, DYN, BEAM, CRSP, NTLA, BBIO, BMRN, ALNY, ALLO, REGN, SRPT and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.